Enabling next-generation drug discovery targeting GPCRs
To leverage our unique platform technology in G protein-coupled receptor (GPCR) drug discovery to fast-track the development of new, transformative medicines for a wide range of patient groups
Rapid generation of scalable GPCR sample preparations for a wide range of downstream research workflows
Custom GPCR assays to enable GPCR optimisation and high screening fidelity
Proprietary LASEREDD screening workflows to identify next-generation GPCR-modulating small molecules and antibodies
Decades of GPCR research and commercialisation experience
LASEREDDtx was proudly founded by researchers from The Florey Institute in Melbourne, Australia in 2022.
Scientists from the Florey Institute of Neuroscience and Mental Health have secured $500,000 in funding to enhance their capacity to undertake next-generation drug discovery through a new biotech spin-out LASEREDD Therapeutics.